Roger D. Tung is CEO at CONCERT PHARMACEUTICALS, INC. (CNCE). They have made 3 open-market trades across 1 company since 2016, most recently 2023-03-06.
CIK 0001594857
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $414K since 2016, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CNCE | 971,018 | $8.1M |
Shares reported on the most recent Form 4, priced at the 2023-01-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CNCE | SELL | 2023-01-06 | 2023-01-09 | $7.24 | $134K | +14.0% | +15.0% | N/A |
| CNCE | SELL · 10b5-1 | 2022-02-15 | 2022-02-16 | $3.09 | $42K | -10.9% | +5.3% | +29.9% |
| CNCE | SELL · 10b5-1 | 2022-01-06 | 2022-01-07 | $3.09 | $29K | -0.6% | +3.2% | +14.3% |
| CNCE | SELL · 10b5-1 | 2021-12-13 | 2021-12-15 | $3.62 | $24K | -5.7% | -10.8% | -20.1% |
| CNCE | SELL | 2021-02-17 | 2021-02-17 | $7.20 | $97K | -4.7% | -14.8% | -44.3% |
| CNCE | BUY | 2016-05-11 | 2016-05-12 | $10.55 | $414K | +29.7% | +18.1% | +6.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.